Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Mo Qatanani Sells 2,315 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Mo Qatanani sold 2,315 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $8.98, for a total transaction of $20,788.70. Following the completion of the transaction, the insider now directly owns 144,704 shares of the company’s stock, valued at approximately $1,299,441.92. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Scholar Rock Stock Down 3.3 %

SRRK opened at $8.49 on Wednesday. The company’s 50 day simple moving average is $12.35 and its two-hundred day simple moving average is $14.90. Scholar Rock Holding Co. has a 1-year low of $5.93 and a 1-year high of $21.17. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.58 and a quick ratio of 6.58.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.11). During the same quarter in the prior year, the business posted ($0.46) EPS. Research analysts anticipate that Scholar Rock Holding Co. will post -2.4 earnings per share for the current year.

Wall Street Analyst Weigh In

SRRK has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Scholar Rock in a report on Tuesday, June 4th. BMO Capital Markets upped their price target on shares of Scholar Rock from $29.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, June 13th. Truist Financial reiterated a “buy” rating and set a $20.00 price objective on shares of Scholar Rock in a report on Wednesday, April 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $28.00 price target on shares of Scholar Rock in a research note on Tuesday, March 26th. Finally, Raymond James started coverage on Scholar Rock in a research note on Thursday, March 28th. They issued a “strong-buy” rating and a $30.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $26.00.

Hedge Funds Weigh In On Scholar Rock

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its stake in shares of Scholar Rock by 62.3% during the third quarter. Barclays PLC now owns 32,318 shares of the company’s stock worth $230,000 after purchasing an additional 12,409 shares in the last quarter. Amalgamated Bank lifted its holdings in Scholar Rock by 52.8% during the 3rd quarter. Amalgamated Bank now owns 4,217 shares of the company’s stock worth $30,000 after buying an additional 1,458 shares during the last quarter. Swiss National Bank boosted its position in shares of Scholar Rock by 5.4% during the 3rd quarter. Swiss National Bank now owns 83,600 shares of the company’s stock worth $594,000 after acquiring an additional 4,300 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new position in shares of Scholar Rock in the 3rd quarter valued at about $88,000. Finally, FMR LLC raised its position in shares of Scholar Rock by 3.8% during the 3rd quarter. FMR LLC now owns 8,005,654 shares of the company’s stock worth $56,840,000 after acquiring an additional 291,156 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.